<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362958</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-005</org_study_id>
    <nct_id>NCT02362958</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer</brief_title>
  <official_title>Sun Yat-sen University Cancer Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the Efficacy of Lapatinib in Combination With Chemotherapy in Patients With
      Trastuzumab-refractory Metastatic HER2-positive Breast Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some studies has demonstrated that even in trastuzumab pretreated patients with HER-2
      positive breast cancer, might benefit from the treatment of trastuzumab. However, there is
      small benefit for some patients having short disease-free survival after adjuvant trastuzumab
      or short progression-free survival after first-line trastuzumab-based therapy. In clinical
      practice, the investigators also found it is fact. And the investigators have a scientific
      rationale for clinical testing of lapatinib plus chemotherapy in patients with
      trastuzumab-refractory, metastatic HER2-positive breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2015</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>36 months</time_frame>
    <description>The time from randomization to disease progression or death from any causes</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>HER2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib and Capecitabine or Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib and capecitabine or vinorelbine</intervention_name>
    <description>lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)</description>
    <arm_group_label>Lapatinib and Capecitabine or Vinorelbine</arm_group_label>
    <other_name>Tykerb; Xeloda;NVB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic breast cancer

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1

          -  HER2-expressing primary or metastatic tumor

          -  Recurrence within 1 year completing adjuvant trastuzumab OR rapid progress following
             first-line trastuzumab-based care.

          -  Measurable disease with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

          -  Normal organ function, including bone marrow function, renal function, liver function,
             and cardiac function

          -  Signed and dated an informed consent form

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  left ventricular ejection fraction (LVEF) &lt; 45% by echocardiogram

          -  Disease-free interval (DFI) less than 12 months

          -  Uncontrolled medical problems

          -  Any previous malignancy exceptions for carcinoma of the cervix, squamous carcinoma of
             the skin, or basal cell carcinoma of the skin

          -  Patients were unable or unwilling to comply with program requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-Yu Yuan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 8, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

